News
Merck & Co/Eisai eye kidney cancer use for immunotherapy com...
Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated p
